Latest filing published 18 Dec 2024 for Regeneron Pharmaceuticals, INC., €211k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Neil Stahl in Regeneron Pharmaceuticals, Inc., where the filings describe the role as senior executive. We count 18 filings; the first trade dates from 25 February 2021 and the latest from 16 December 2024.
On the market, this insider has only sold: 2 sales, €187k in total. Besides market trades, the filings include 6 share grants and 3 option exercises. Since January 2024: no purchases and 2 sales on the market.
The newest entry dates from 18 December 2024: a share grant of €211k, in Regeneron Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
18 of 18 declarations